| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nutrition Therapy | 2 | 2019 | 102 | 1.220 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 1664 | 0.790 |
Why?
|
| Drug Approval | 3 | 2020 | 814 | 0.650 |
Why?
|
| Progestins | 1 | 2020 | 301 | 0.620 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2018 | 25 | 0.610 |
Why?
|
| Biometry | 4 | 2008 | 563 | 0.600 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 737 | 0.500 |
Why?
|
| HIV Protease | 2 | 2005 | 97 | 0.480 |
Why?
|
| Regional Health Planning | 2 | 2014 | 96 | 0.470 |
Why?
|
| Antiviral Agents | 3 | 2020 | 3060 | 0.440 |
Why?
|
| Burn Units | 1 | 2014 | 143 | 0.440 |
Why?
|
| Angiography | 21 | 1990 | 1595 | 0.380 |
Why?
|
| Biological Products | 1 | 2018 | 914 | 0.320 |
Why?
|
| Confidentiality | 1 | 2013 | 609 | 0.320 |
Why?
|
| Linear Models | 4 | 2010 | 5872 | 0.310 |
Why?
|
| Likelihood Functions | 4 | 2002 | 992 | 0.310 |
Why?
|
| Premature Birth | 1 | 2020 | 1782 | 0.310 |
Why?
|
| Regression Analysis | 13 | 2010 | 6344 | 0.300 |
Why?
|
| Burns | 2 | 2023 | 1882 | 0.300 |
Why?
|
| Disclosure | 1 | 2013 | 748 | 0.280 |
Why?
|
| Quality Assurance, Health Care | 2 | 2014 | 2169 | 0.270 |
Why?
|
| Angioplasty, Balloon | 8 | 1995 | 589 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3206 | 0.250 |
Why?
|
| Models, Statistical | 9 | 2015 | 5079 | 0.250 |
Why?
|
| Repressor Proteins | 1 | 2016 | 2986 | 0.250 |
Why?
|
| Neoplasms | 10 | 2019 | 22173 | 0.240 |
Why?
|
| Patients | 1 | 2010 | 907 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2004 | 10212 | 0.220 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 15501 | 0.220 |
Why?
|
| Health Surveys | 2 | 2013 | 4061 | 0.220 |
Why?
|
| Research Personnel | 1 | 2008 | 588 | 0.210 |
Why?
|
| Patient Satisfaction | 3 | 2012 | 3461 | 0.200 |
Why?
|
| Femoral Vein | 2 | 1995 | 153 | 0.200 |
Why?
|
| Subtraction Technique | 6 | 1985 | 512 | 0.190 |
Why?
|
| Graft Occlusion, Vascular | 6 | 1994 | 537 | 0.190 |
Why?
|
| Equipment and Supplies, Hospital | 2 | 1991 | 56 | 0.190 |
Why?
|
| Renal Circulation | 5 | 1989 | 291 | 0.190 |
Why?
|
| Meta-Analysis as Topic | 2 | 1999 | 1380 | 0.180 |
Why?
|
| Colorectal Neoplasms | 5 | 2013 | 6935 | 0.180 |
Why?
|
| Asthma | 2 | 2018 | 6234 | 0.180 |
Why?
|
| Clinical Trials as Topic | 10 | 2020 | 8002 | 0.180 |
Why?
|
| Humans | 151 | 2023 | 761572 | 0.180 |
Why?
|
| Femoral Artery | 8 | 1994 | 826 | 0.170 |
Why?
|
| Drug Resistance, Viral | 1 | 2005 | 862 | 0.170 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2019 | 7 | 0.170 |
Why?
|
| Liver Abscess, Amebic | 1 | 2019 | 20 | 0.170 |
Why?
|
| Lung Neoplasms | 9 | 2013 | 13382 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2010 | 11742 | 0.160 |
Why?
|
| Research Design | 7 | 2019 | 6180 | 0.160 |
Why?
|
| Immunization, Passive | 1 | 2020 | 616 | 0.150 |
Why?
|
| Esophageal Neoplasms | 4 | 2013 | 1654 | 0.150 |
Why?
|
| Taxoids | 4 | 2007 | 668 | 0.150 |
Why?
|
| Carbamates | 1 | 2019 | 191 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2002 | 192 | 0.140 |
Why?
|
| Drugs, Investigational | 1 | 1999 | 212 | 0.140 |
Why?
|
| Cicatrix | 1 | 2023 | 798 | 0.140 |
Why?
|
| Renal Artery Obstruction | 8 | 1986 | 219 | 0.140 |
Why?
|
| Aortography | 2 | 1992 | 421 | 0.140 |
Why?
|
| Leg | 6 | 1995 | 1088 | 0.140 |
Why?
|
| Ethics, Medical | 2 | 1999 | 783 | 0.140 |
Why?
|
| Deoxycytidine | 4 | 2007 | 877 | 0.130 |
Why?
|
| Proportional Hazards Models | 5 | 2008 | 12463 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2004 | 857 | 0.130 |
Why?
|
| Quality of Health Care | 2 | 2010 | 4330 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 426 | 0.130 |
Why?
|
| Survival Analysis | 17 | 2019 | 10090 | 0.130 |
Why?
|
| Vitamin D | 2 | 2019 | 3303 | 0.130 |
Why?
|
| Trust | 1 | 2020 | 530 | 0.130 |
Why?
|
| Popliteal Vein | 1 | 1995 | 43 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 4 | 2009 | 2691 | 0.120 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 478 | 0.120 |
Why?
|
| Ovary | 1 | 2019 | 959 | 0.120 |
Why?
|
| Maintenance and Engineering, Hospital | 2 | 1991 | 6 | 0.120 |
Why?
|
| Logistic Models | 5 | 2016 | 13255 | 0.120 |
Why?
|
| Vascular Patency | 4 | 1995 | 911 | 0.120 |
Why?
|
| Fluorouracil | 4 | 2007 | 1642 | 0.120 |
Why?
|
| Colonic Neoplasms | 2 | 1999 | 2538 | 0.120 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 4878 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2001 | 2644 | 0.120 |
Why?
|
| Health Status Disparities | 2 | 2020 | 1852 | 0.120 |
Why?
|
| World Health Organization | 1 | 2020 | 1322 | 0.120 |
Why?
|
| Vasodilator Agents | 3 | 1989 | 973 | 0.110 |
Why?
|
| Stromal Cells | 1 | 2019 | 1330 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 2001 | 1374 | 0.110 |
Why?
|
| Suture Techniques | 1 | 2019 | 769 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2010 | 15266 | 0.110 |
Why?
|
| Aortic Aneurysm | 2 | 1992 | 648 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 6 | 1990 | 748 | 0.110 |
Why?
|
| Least-Squares Analysis | 1 | 1994 | 369 | 0.110 |
Why?
|
| Popliteal Artery | 4 | 1994 | 310 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 5 | 1995 | 951 | 0.110 |
Why?
|
| Female | 77 | 2020 | 392686 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2016 | 23447 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2018 | 574 | 0.110 |
Why?
|
| Urokinase-Type Plasminogen Activator | 4 | 1990 | 325 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2014 | 4026 | 0.100 |
Why?
|
| United States | 11 | 2020 | 72335 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3086 | 0.100 |
Why?
|
| Catheterization | 6 | 1983 | 1428 | 0.100 |
Why?
|
| Stomach Neoplasms | 3 | 2007 | 1459 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2019 | 1336 | 0.100 |
Why?
|
| Anastomosis, Surgical | 1 | 1995 | 983 | 0.100 |
Why?
|
| Paclitaxel | 3 | 2006 | 1732 | 0.100 |
Why?
|
| Ischemia | 7 | 1995 | 1883 | 0.100 |
Why?
|
| Filtration | 2 | 1990 | 228 | 0.100 |
Why?
|
| Vasomotor System | 2 | 1989 | 207 | 0.100 |
Why?
|
| Gene Dosage | 2 | 2006 | 1218 | 0.100 |
Why?
|
| Bariatric Surgery | 2 | 2012 | 992 | 0.090 |
Why?
|
| Hospital Departments | 2 | 1989 | 134 | 0.090 |
Why?
|
| Nuclear Family | 2 | 2006 | 311 | 0.090 |
Why?
|
| Organizational Innovation | 1 | 2014 | 537 | 0.090 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 1994 | 292 | 0.090 |
Why?
|
| Treatment Outcome | 11 | 2019 | 64684 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2003 | 2510 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2016 | 1206 | 0.090 |
Why?
|
| RNA, Viral | 3 | 2019 | 2846 | 0.090 |
Why?
|
| Mathematical Computing | 1 | 1990 | 142 | 0.090 |
Why?
|
| Granulomatous Disease, Chronic | 2 | 2001 | 173 | 0.090 |
Why?
|
| Recurrence | 3 | 2003 | 8466 | 0.090 |
Why?
|
| Middle Aged | 62 | 2019 | 220920 | 0.080 |
Why?
|
| Male | 65 | 2019 | 360842 | 0.080 |
Why?
|
| Lung Transplantation | 1 | 2019 | 1310 | 0.080 |
Why?
|
| Multiple Myeloma | 6 | 2003 | 5146 | 0.080 |
Why?
|
| Neoplasm Staging | 7 | 2013 | 11121 | 0.080 |
Why?
|
| Prenatal Care | 1 | 2016 | 1139 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2005 | 4527 | 0.080 |
Why?
|
| Diltiazem | 2 | 1987 | 131 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2019 | 1584 | 0.080 |
Why?
|
| Program Evaluation | 2 | 2014 | 2495 | 0.080 |
Why?
|
| Health Services Research | 3 | 2013 | 1812 | 0.080 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2012 | 277 | 0.080 |
Why?
|
| Deglutition Disorders | 1 | 2014 | 625 | 0.080 |
Why?
|
| Aged | 47 | 2019 | 169310 | 0.080 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2012 | 1875 | 0.080 |
Why?
|
| Breast Neoplasms | 8 | 2013 | 21017 | 0.070 |
Why?
|
| Disaster Planning | 1 | 2014 | 557 | 0.070 |
Why?
|
| Cesarean Section | 1 | 2016 | 1398 | 0.070 |
Why?
|
| Models, Genetic | 3 | 2006 | 3442 | 0.070 |
Why?
|
| Chromosome Aberrations | 3 | 2003 | 1768 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2018 | 2979 | 0.070 |
Why?
|
| HIV-1 | 1 | 2004 | 6863 | 0.070 |
Why?
|
| Carboplatin | 2 | 2007 | 794 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2012 | 909 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 3514 | 0.070 |
Why?
|
| Interviews as Topic | 3 | 2013 | 2696 | 0.070 |
Why?
|
| Vena Cava, Inferior | 2 | 1988 | 458 | 0.070 |
Why?
|
| Data Collection | 3 | 2012 | 3322 | 0.070 |
Why?
|
| Reference Standards | 1 | 1990 | 1003 | 0.070 |
Why?
|
| Prognosis | 19 | 2019 | 29629 | 0.070 |
Why?
|
| Polyglutamic Acid | 1 | 2006 | 47 | 0.070 |
Why?
|
| Adult | 51 | 2019 | 221203 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 2373 | 0.070 |
Why?
|
| Radiography, Interventional | 2 | 1993 | 1121 | 0.060 |
Why?
|
| Heart Transplantation | 1 | 2019 | 3233 | 0.060 |
Why?
|
| Genetic Testing | 2 | 1997 | 3537 | 0.060 |
Why?
|
| Postoperative Complications | 6 | 2016 | 15633 | 0.060 |
Why?
|
| Arteriovenous Fistula | 1 | 1988 | 319 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 1995 | 1998 | 0.060 |
Why?
|
| Length of Stay | 2 | 2018 | 6426 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1349 | 0.060 |
Why?
|
| Antineoplastic Agents | 4 | 2006 | 13642 | 0.060 |
Why?
|
| Prednisone | 7 | 2001 | 1563 | 0.060 |
Why?
|
| Alleles | 2 | 2006 | 6864 | 0.060 |
Why?
|
| Models, Biological | 1 | 2001 | 9469 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 1924 | 0.060 |
Why?
|
| Acetylcholine | 2 | 1987 | 629 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 350 | 0.060 |
Why?
|
| Computers | 5 | 1985 | 593 | 0.060 |
Why?
|
| Computer Simulation | 5 | 2014 | 6241 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 1992 | 834 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1990 | 1192 | 0.060 |
Why?
|
| Radiographic Image Enhancement | 3 | 1987 | 876 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1990 | 1164 | 0.060 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 1964 | 0.060 |
Why?
|
| Specialization | 1 | 1989 | 778 | 0.060 |
Why?
|
| Lymphoma | 3 | 1988 | 1901 | 0.060 |
Why?
|
| Cyclophosphamide | 8 | 2001 | 2220 | 0.060 |
Why?
|
| Patient Care Team | 2 | 2016 | 2521 | 0.060 |
Why?
|
| Inpatients | 1 | 2015 | 2548 | 0.060 |
Why?
|
| Benzazepines | 1 | 1985 | 310 | 0.050 |
Why?
|
| Renal Veins | 2 | 1981 | 102 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 8656 | 0.050 |
Why?
|
| Duodenum | 3 | 1983 | 490 | 0.050 |
Why?
|
| Hypertension, Renovascular | 2 | 1983 | 116 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2019 | 4793 | 0.050 |
Why?
|
| Esophagogastric Junction | 1 | 2005 | 347 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2426 | 0.050 |
Why?
|
| Aneurysm | 2 | 1983 | 337 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 1990 | 1779 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 2947 | 0.050 |
Why?
|
| Renin | 3 | 1981 | 641 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2001 | 3162 | 0.050 |
Why?
|
| Leukemia, Myeloid | 2 | 1998 | 694 | 0.050 |
Why?
|
| DNA, Neoplasm | 3 | 2005 | 1745 | 0.050 |
Why?
|
| Disease-Free Survival | 5 | 2013 | 6815 | 0.050 |
Why?
|
| Pregnancy | 4 | 2020 | 29876 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 1985 | 694 | 0.050 |
Why?
|
| Risk Factors | 9 | 2020 | 74213 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2009 | 5315 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2850 | 0.050 |
Why?
|
| Transplantation, Autologous | 3 | 2023 | 2115 | 0.050 |
Why?
|
| Embolization, Therapeutic | 5 | 1991 | 1418 | 0.050 |
Why?
|
| Rhode Island | 2 | 2019 | 351 | 0.050 |
Why?
|
| Leucovorin | 4 | 1999 | 643 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2014 | 3905 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 9420 | 0.050 |
Why?
|
| Ketanserin | 2 | 1992 | 24 | 0.050 |
Why?
|
| Adenocarcinoma | 3 | 2009 | 6346 | 0.050 |
Why?
|
| Fluoxymesterone | 1 | 2001 | 12 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2002 | 287 | 0.050 |
Why?
|
| Monosomy | 1 | 2001 | 52 | 0.050 |
Why?
|
| HIV Infections | 2 | 2005 | 17352 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2002 | 249 | 0.050 |
Why?
|
| Birth Rate | 1 | 2002 | 168 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2005 | 1089 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 1277 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2002 | 410 | 0.050 |
Why?
|
| Brachiocephalic Trunk | 1 | 1981 | 40 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 1990 | 2064 | 0.050 |
Why?
|
| Language | 1 | 2010 | 1540 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 1981 | 135 | 0.050 |
Why?
|
| Captopril | 1 | 1981 | 265 | 0.050 |
Why?
|
| Pilot Projects | 5 | 2019 | 8633 | 0.050 |
Why?
|
| Physician-Patient Relations | 2 | 2012 | 3249 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2005 | 2079 | 0.040 |
Why?
|
| Medicine | 1 | 1989 | 942 | 0.040 |
Why?
|
| Renal Artery | 6 | 1987 | 351 | 0.040 |
Why?
|
| Angiotensin II | 4 | 1989 | 849 | 0.040 |
Why?
|
| Cytarabine | 3 | 1998 | 698 | 0.040 |
Why?
|
| Mutation | 1 | 2004 | 30054 | 0.040 |
Why?
|
| Chromosome Deletion | 2 | 2003 | 1386 | 0.040 |
Why?
|
| Hypertension | 5 | 1989 | 8540 | 0.040 |
Why?
|
| Spouses | 1 | 2002 | 283 | 0.040 |
Why?
|
| Streptococcus milleri Group | 1 | 2019 | 6 | 0.040 |
Why?
|
| Communication | 2 | 2012 | 3873 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2008 | 2767 | 0.040 |
Why?
|
| Translocation, Genetic | 2 | 2003 | 1393 | 0.040 |
Why?
|
| Arteriosclerosis | 3 | 1992 | 1055 | 0.040 |
Why?
|
| Microdissection | 1 | 2019 | 151 | 0.040 |
Why?
|
| Proline | 1 | 1981 | 457 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 1981 | 238 | 0.040 |
Why?
|
| Aged, 80 and over | 17 | 2013 | 58986 | 0.040 |
Why?
|
| Preoperative Care | 4 | 2012 | 2242 | 0.040 |
Why?
|
| Uncertainty | 1 | 2004 | 754 | 0.040 |
Why?
|
| Software | 2 | 2009 | 4434 | 0.040 |
Why?
|
| Biliary Tract | 1 | 1980 | 135 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2004 | 960 | 0.040 |
Why?
|
| London | 1 | 2019 | 234 | 0.040 |
Why?
|
| Cluster Analysis | 3 | 2015 | 2707 | 0.040 |
Why?
|
| Leukemia, Hairy Cell | 2 | 1991 | 82 | 0.040 |
Why?
|
| Developing Countries | 1 | 1991 | 2885 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 2019 | 146 | 0.040 |
Why?
|
| Vincristine | 8 | 1998 | 1036 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 8552 | 0.040 |
Why?
|
| Streptococcus | 1 | 2019 | 198 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 1 | 2019 | 263 | 0.040 |
Why?
|
| Methotrexate | 4 | 2001 | 1719 | 0.040 |
Why?
|
| Antidotes | 1 | 1999 | 138 | 0.040 |
Why?
|
| Iliac Artery | 5 | 1986 | 343 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 4016 | 0.040 |
Why?
|
| Follow-Up Studies | 14 | 2018 | 39107 | 0.040 |
Why?
|
| Kidney | 2 | 1985 | 7047 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2023 | 1083 | 0.040 |
Why?
|
| Hematoma | 1 | 1983 | 767 | 0.040 |
Why?
|
| Radiography | 14 | 1992 | 6965 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 2 | 1998 | 2693 | 0.040 |
Why?
|
| Rural Population | 2 | 2013 | 2285 | 0.040 |
Why?
|
| Sample Size | 1 | 2001 | 841 | 0.040 |
Why?
|
| Markov Chains | 1 | 2001 | 966 | 0.040 |
Why?
|
| Mortality | 1 | 1988 | 2901 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2001 | 1494 | 0.030 |
Why?
|
| Pancreas | 2 | 1983 | 1691 | 0.030 |
Why?
|
| Registries | 1 | 2013 | 8224 | 0.030 |
Why?
|
| Remission Induction | 8 | 1998 | 2397 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2006 | 15936 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2001 | 965 | 0.030 |
Why?
|
| Sodium | 1 | 1981 | 1588 | 0.030 |
Why?
|
| Pregnancy, Unplanned | 1 | 2016 | 85 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 20099 | 0.030 |
Why?
|
| Aorta, Abdominal | 2 | 1992 | 625 | 0.030 |
Why?
|
| Drug Administration Schedule | 7 | 2010 | 4853 | 0.030 |
Why?
|
| Veins | 3 | 1990 | 768 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2001 | 2927 | 0.030 |
Why?
|
| Intermittent Claudication | 2 | 1995 | 304 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2005 | 2571 | 0.030 |
Why?
|
| Norepinephrine | 2 | 1989 | 897 | 0.030 |
Why?
|
| Breast Diseases | 1 | 1978 | 442 | 0.030 |
Why?
|
| Bleomycin | 6 | 1998 | 494 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 6075 | 0.030 |
Why?
|
| Cohort Studies | 7 | 2019 | 41493 | 0.030 |
Why?
|
| Aorta, Thoracic | 2 | 1981 | 1096 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 1039 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 1991 | 9280 | 0.030 |
Why?
|
| Fibrinolytic Agents | 3 | 1990 | 2084 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1998 | 646 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 1989 | 3530 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 3358 | 0.030 |
Why?
|
| Polysomnography | 2 | 2012 | 1848 | 0.030 |
Why?
|
| Transplants | 1 | 2016 | 206 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 5821 | 0.030 |
Why?
|
| Kidney Diseases | 2 | 1983 | 2091 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2015 | 615 | 0.030 |
Why?
|
| Pentostatin | 2 | 1991 | 26 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 551 | 0.030 |
Why?
|
| Constriction, Pathologic | 2 | 1995 | 1096 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2006 | 883 | 0.030 |
Why?
|
| Statistics as Topic | 3 | 2012 | 2358 | 0.030 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2013 | 31 | 0.030 |
Why?
|
| Rhizopus | 1 | 1992 | 22 | 0.030 |
Why?
|
| Radiology Department, Hospital | 2 | 1989 | 406 | 0.030 |
Why?
|
| Streptokinase | 3 | 1989 | 186 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1995 | 488 | 0.030 |
Why?
|
| Doxorubicin | 7 | 1998 | 2224 | 0.030 |
Why?
|
| Saphenous Vein | 1 | 1995 | 516 | 0.030 |
Why?
|
| Retrospective Studies | 9 | 2019 | 80646 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 1996 | 732 | 0.030 |
Why?
|
| Wound Healing | 1 | 2023 | 2805 | 0.030 |
Why?
|
| Time Factors | 8 | 2019 | 39970 | 0.020 |
Why?
|
| Tarsal Bones | 1 | 1992 | 70 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1997 | 604 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2019 | 1255 | 0.020 |
Why?
|
| Charities | 1 | 1991 | 33 | 0.020 |
Why?
|
| Troponin I | 1 | 2016 | 651 | 0.020 |
Why?
|
| Mucormycosis | 1 | 1992 | 103 | 0.020 |
Why?
|
| Combined Modality Therapy | 5 | 2006 | 8528 | 0.020 |
Why?
|
| Interphase | 2 | 2002 | 228 | 0.020 |
Why?
|
| Sarcoidosis | 2 | 1996 | 521 | 0.020 |
Why?
|
| Dilatation and Curettage | 1 | 1991 | 52 | 0.020 |
Why?
|
| Polonium | 1 | 1990 | 2 | 0.020 |
Why?
|
| Threshold Limit Values | 1 | 2010 | 12 | 0.020 |
Why?
|
| Bismuth | 1 | 1990 | 29 | 0.020 |
Why?
|
| Osteonecrosis | 1 | 1992 | 229 | 0.020 |
Why?
|
| Vasopressins | 3 | 1977 | 351 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1977 | 783 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2018 | 1836 | 0.020 |
Why?
|
| Coronary Disease | 4 | 1987 | 5914 | 0.020 |
Why?
|
| Odds Ratio | 4 | 2004 | 9646 | 0.020 |
Why?
|
| Kenya | 1 | 2013 | 758 | 0.020 |
Why?
|
| Relaxation | 1 | 1990 | 51 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 1378 | 0.020 |
Why?
|
| Software Design | 1 | 1990 | 171 | 0.020 |
Why?
|
| Age Factors | 3 | 2019 | 18398 | 0.020 |
Why?
|
| Skin | 1 | 2023 | 4484 | 0.020 |
Why?
|
| Random Allocation | 4 | 2004 | 2395 | 0.020 |
Why?
|
| Emergencies | 1 | 2016 | 1217 | 0.020 |
Why?
|
| Pregnancy, Ectopic | 1 | 1991 | 142 | 0.020 |
Why?
|
| Young Adult | 3 | 2010 | 59255 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 14666 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2019 | 2332 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 6 | 1990 | 182 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 15843 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 1990 | 602 | 0.020 |
Why?
|
| Platelet Activation | 1 | 1992 | 645 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 1992 | 407 | 0.020 |
Why?
|
| Coronary Angiography | 3 | 1987 | 4471 | 0.020 |
Why?
|
| Life Expectancy | 1 | 1995 | 1242 | 0.020 |
Why?
|
| Graft Survival | 1 | 2019 | 3820 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 1993 | 1129 | 0.020 |
Why?
|
| Obesity | 1 | 2010 | 12947 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2001 | 2491 | 0.020 |
Why?
|
| Survival Rate | 5 | 2009 | 12725 | 0.020 |
Why?
|
| Population Surveillance | 2 | 2013 | 2598 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2009 | 297 | 0.020 |
Why?
|
| Cisplatin | 3 | 2002 | 1652 | 0.020 |
Why?
|
| SEER Program | 1 | 2013 | 1450 | 0.020 |
Why?
|
| Biostatistics | 1 | 2009 | 164 | 0.020 |
Why?
|
| Coformycin | 1 | 1987 | 11 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2016 | 7967 | 0.020 |
Why?
|
| Community Health Services | 1 | 2012 | 656 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2006 | 3778 | 0.020 |
Why?
|
| Injections, Intravenous | 3 | 1985 | 1379 | 0.020 |
Why?
|
| Arteries | 1 | 1992 | 1123 | 0.020 |
Why?
|
| Punctures | 1 | 1988 | 366 | 0.020 |
Why?
|
| Pulmonary Artery | 2 | 1986 | 1927 | 0.020 |
Why?
|
| Dilatation | 1 | 1988 | 306 | 0.020 |
Why?
|
| Ribonucleosides | 1 | 1987 | 79 | 0.020 |
Why?
|
| Uterus | 1 | 1991 | 649 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 2629 | 0.020 |
Why?
|
| Prospective Studies | 8 | 2009 | 54426 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 1991 | 638 | 0.020 |
Why?
|
| Thrombosis | 3 | 1990 | 2942 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3877 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 1297 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1978 | 3424 | 0.020 |
Why?
|
| Sleep Stages | 1 | 2010 | 694 | 0.020 |
Why?
|
| Dogs | 4 | 1985 | 3839 | 0.020 |
Why?
|
| Cineangiography | 1 | 1985 | 108 | 0.020 |
Why?
|
| Selection Bias | 1 | 2008 | 359 | 0.020 |
Why?
|
| Dysgerminoma | 1 | 1985 | 66 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 1990 | 702 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2019 | 4446 | 0.020 |
Why?
|
| Housing | 1 | 1990 | 670 | 0.020 |
Why?
|
| Pathology | 1 | 1988 | 270 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1992 | 36429 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12059 | 0.020 |
Why?
|
| Kidney Neoplasms | 2 | 1983 | 4251 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 1988 | 343 | 0.020 |
Why?
|
| Adolescent | 10 | 2010 | 88324 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 2 | 1986 | 1578 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 1993 | 2208 | 0.010 |
Why?
|
| General Surgery | 1 | 2016 | 1692 | 0.010 |
Why?
|
| Neutropenia | 2 | 2005 | 885 | 0.010 |
Why?
|
| Lead | 1 | 1990 | 879 | 0.010 |
Why?
|
| Risk | 2 | 2001 | 9610 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2009 | 928 | 0.010 |
Why?
|
| ROC Curve | 1 | 1992 | 3579 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 1981 | 4671 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2006 | 662 | 0.010 |
Why?
|
| Procarbazine | 2 | 1998 | 172 | 0.010 |
Why?
|
| Genome, Human | 1 | 1997 | 4425 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2005 | 441 | 0.010 |
Why?
|
| Child | 4 | 2001 | 80156 | 0.010 |
Why?
|
| Embolism | 2 | 1977 | 399 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 1405 | 0.010 |
Why?
|
| Television | 2 | 1984 | 408 | 0.010 |
Why?
|
| Carmustine | 2 | 1997 | 138 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6484 | 0.010 |
Why?
|
| Menopause | 1 | 1991 | 1646 | 0.010 |
Why?
|
| Radiotherapy, Conformal | 1 | 2006 | 548 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1990 | 1189 | 0.010 |
Why?
|
| Quality of Life | 3 | 2006 | 13367 | 0.010 |
Why?
|
| Adenoma, Islet Cell | 1 | 1982 | 72 | 0.010 |
Why?
|
| Mesenteric Arteries | 3 | 1977 | 178 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 2223 | 0.010 |
Why?
|
| Hepatic Veins | 3 | 1977 | 112 | 0.010 |
Why?
|
| Gambia | 1 | 2002 | 104 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1993 | 5869 | 0.010 |
Why?
|
| Hospice Care | 1 | 2009 | 678 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 679 | 0.010 |
Why?
|
| Retroperitoneal Space | 1 | 1983 | 170 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1995 | 5492 | 0.010 |
Why?
|
| Technology, Radiologic | 1 | 1982 | 160 | 0.010 |
Why?
|
| Ion Channels | 1 | 1987 | 1040 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1983 | 362 | 0.010 |
Why?
|
| Insulinoma | 1 | 1982 | 121 | 0.010 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 1981 | 55 | 0.010 |
Why?
|
| Extremities | 1 | 1987 | 867 | 0.010 |
Why?
|
| Ploidies | 1 | 2002 | 285 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 1993 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 2016 | 26198 | 0.010 |
Why?
|
| Contrast Media | 3 | 1985 | 5311 | 0.010 |
Why?
|
| Hemodynamics | 3 | 1990 | 4160 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1990 | 6228 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1981 | 221 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 1987 | 981 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1997 | 6567 | 0.010 |
Why?
|
| Vinblastine | 2 | 1998 | 488 | 0.010 |
Why?
|
| Genotype | 2 | 2006 | 12990 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2002 | 285 | 0.010 |
Why?
|
| Life Tables | 2 | 1993 | 364 | 0.010 |
Why?
|
| Bradykinin | 1 | 1981 | 208 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 1638 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2002 | 329 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1994 | 2781 | 0.010 |
Why?
|
| Thromboembolism | 1 | 1987 | 995 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 793 | 0.010 |
Why?
|
| Lung | 3 | 1990 | 10002 | 0.010 |
Why?
|
| Thioguanine | 2 | 1992 | 45 | 0.010 |
Why?
|
| Marriage | 1 | 2002 | 351 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1981 | 232 | 0.010 |
Why?
|
| Blood Pressure | 3 | 1983 | 8481 | 0.010 |
Why?
|
| Aspirin | 1 | 1992 | 3133 | 0.010 |
Why?
|
| Comprehension | 1 | 2006 | 621 | 0.010 |
Why?
|
| DNA Probes | 1 | 2001 | 541 | 0.010 |
Why?
|
| Subclavian Artery | 1 | 1981 | 133 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1990 | 6534 | 0.010 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1982 | 161 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2003 | 647 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 2895 | 0.010 |
Why?
|
| Leukemia | 1 | 1988 | 1522 | 0.010 |
Why?
|
| Equipment Design | 2 | 1990 | 3511 | 0.010 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1981 | 292 | 0.010 |
Why?
|
| Mothers | 1 | 1990 | 2198 | 0.010 |
Why?
|
| Haplotypes | 1 | 2005 | 2713 | 0.010 |
Why?
|
| Methods | 2 | 1985 | 1067 | 0.010 |
Why?
|
| Liver Neoplasms | 3 | 2005 | 4319 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7827 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2006 | 3606 | 0.010 |
Why?
|
| Age of Onset | 1 | 2006 | 3306 | 0.010 |
Why?
|
| Posture | 1 | 1983 | 957 | 0.010 |
Why?
|
| Acute Disease | 3 | 1998 | 7237 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2019 | 5882 | 0.010 |
Why?
|
| Plasma Cells | 1 | 2002 | 599 | 0.010 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 1979 | 296 | 0.010 |
Why?
|
| Mammary Arteries | 1 | 1978 | 81 | 0.010 |
Why?
|
| Cholelithiasis | 1 | 1979 | 407 | 0.010 |
Why?
|
| Aneurysm, Infected | 1 | 1978 | 82 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1998 | 129 | 0.010 |
Why?
|
| Sex Factors | 1 | 2012 | 10553 | 0.010 |
Why?
|
| Dexamethasone | 3 | 1992 | 1948 | 0.010 |
Why?
|
| Pediatrics | 1 | 1973 | 3589 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1992 | 12341 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1994 | 14607 | 0.010 |
Why?
|
| Arteriovenous Malformations | 1 | 1980 | 396 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 1648 | 0.010 |
Why?
|
| Stomach | 1 | 1981 | 696 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 641 | 0.010 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1977 | 92 | 0.010 |
Why?
|
| Incidence | 2 | 1996 | 21355 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 1981 | 941 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1997 | 284 | 0.010 |
Why?
|
| Ureteral Neoplasms | 1 | 1977 | 107 | 0.010 |
Why?
|
| Mass Screening | 1 | 2012 | 5428 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1998 | 10766 | 0.010 |
Why?
|
| Melphalan | 1 | 1997 | 420 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5440 | 0.010 |
Why?
|
| Michigan | 1 | 1996 | 339 | 0.010 |
Why?
|
| Anxiety | 1 | 1990 | 4573 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 16592 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 5247 | 0.010 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1977 | 208 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2001 | 2601 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1998 | 559 | 0.010 |
Why?
|
| Hypertension, Portal | 1 | 1977 | 226 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1977 | 957 | 0.010 |
Why?
|
| Pain | 1 | 1990 | 5073 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2016 | 23996 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 2417 | 0.010 |
Why?
|
| Quantitative Trait, Heritable | 1 | 1997 | 543 | 0.010 |
Why?
|
| Smoking | 1 | 1990 | 9053 | 0.010 |
Why?
|
| Transplantation, Homologous | 2 | 1998 | 4807 | 0.010 |
Why?
|
| Diploidy | 1 | 1993 | 132 | 0.010 |
Why?
|
| Vasodilation | 2 | 1992 | 962 | 0.010 |
Why?
|
| G2 Phase | 1 | 1993 | 136 | 0.010 |
Why?
|
| Heart | 1 | 1986 | 4404 | 0.010 |
Why?
|
| Health Status | 1 | 2006 | 4077 | 0.010 |
Why?
|
| Plastics | 1 | 1973 | 117 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2010 | 12954 | 0.010 |
Why?
|
| Polyploidy | 1 | 1993 | 119 | 0.010 |
Why?
|
| Gastritis | 1 | 1974 | 199 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 1985 | 2567 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1997 | 1519 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 5841 | 0.010 |
Why?
|
| Decision Making | 1 | 2006 | 3929 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1998 | 1590 | 0.010 |
Why?
|
| G1 Phase | 1 | 1993 | 403 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2002 | 2922 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 2644 | 0.010 |
Why?
|
| B-Lymphocytes | 3 | 1990 | 4758 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1983 | 20571 | 0.010 |
Why?
|
| Adenoma | 1 | 1982 | 2160 | 0.010 |
Why?
|
| Radon Daughters | 1 | 1990 | 11 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2001 | 2911 | 0.010 |
Why?
|
| Alcoholism | 3 | 1977 | 1973 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1977 | 1116 | 0.010 |
Why?
|
| Epinephrine | 1 | 1974 | 792 | 0.010 |
Why?
|
| Polyethylenes | 1 | 1973 | 290 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1996 | 2341 | 0.010 |
Why?
|
| Tape Recording | 1 | 1990 | 77 | 0.010 |
Why?
|
| Air Pollutants, Radioactive | 1 | 1990 | 52 | 0.010 |
Why?
|
| Needles | 1 | 1973 | 451 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2001 | 2630 | 0.010 |
Why?
|
| Patient Selection | 1 | 2001 | 4244 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1992 | 592 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1993 | 552 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1989 | 317 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1052 | 0.010 |
Why?
|
| Diazepam | 1 | 1990 | 215 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 16986 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1977 | 1298 | 0.000 |
Why?
|
| Multi-Institutional Systems | 1 | 1988 | 43 | 0.000 |
Why?
|
| Relaxation Therapy | 1 | 1990 | 181 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1997 | 4615 | 0.000 |
Why?
|
| Daunorubicin | 1 | 1988 | 157 | 0.000 |
Why?
|
| Pedigree | 1 | 1996 | 4542 | 0.000 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1988 | 228 | 0.000 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1989 | 898 | 0.000 |
Why?
|
| Intensive Care Units | 1 | 2001 | 3744 | 0.000 |
Why?
|
| T-Lymphocytes | 3 | 1990 | 10194 | 0.000 |
Why?
|
| Music | 1 | 1990 | 245 | 0.000 |
Why?
|
| Cervix Uteri | 1 | 1991 | 570 | 0.000 |
Why?
|
| Fentanyl | 1 | 1990 | 434 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 3416 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1990 | 1085 | 0.000 |
Why?
|
| Clinical Protocols | 1 | 1992 | 1440 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1988 | 1624 | 0.000 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1986 | 273 | 0.000 |
Why?
|
| Algorithms | 1 | 2006 | 14032 | 0.000 |
Why?
|
| Splenectomy | 1 | 1987 | 391 | 0.000 |
Why?
|
| Multicenter Studies as Topic | 1 | 1990 | 1702 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1990 | 520 | 0.000 |
Why?
|
| Serotonin | 1 | 1990 | 1041 | 0.000 |
Why?
|
| Computer Systems | 1 | 1987 | 470 | 0.000 |
Why?
|
| Leukopenia | 1 | 1985 | 213 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1993 | 3597 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1982 | 5369 | 0.000 |
Why?
|
| Disease Progression | 1 | 2001 | 13510 | 0.000 |
Why?
|
| Diatrizoate Meglumine | 1 | 1983 | 79 | 0.000 |
Why?
|
| Kidney Transplantation | 1 | 1979 | 4235 | 0.000 |
Why?
|
| Prospective Payment System | 1 | 1984 | 136 | 0.000 |
Why?
|
| Interferons | 1 | 1987 | 706 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1987 | 1371 | 0.000 |
Why?
|
| Costs and Cost Analysis | 1 | 1988 | 1668 | 0.000 |
Why?
|
| Liver Cirrhosis | 3 | 1977 | 1935 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1983 | 11461 | 0.000 |
Why?
|
| Transducers | 1 | 1983 | 244 | 0.000 |
Why?
|
| Floxuridine | 1 | 1981 | 44 | 0.000 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 1985 | 477 | 0.000 |
Why?
|
| Cost Control | 1 | 1984 | 628 | 0.000 |
Why?
|
| Aorta | 2 | 1979 | 2041 | 0.000 |
Why?
|
| Infant | 3 | 1985 | 36192 | 0.000 |
Why?
|
| Hemangioendothelioma | 1 | 1980 | 111 | 0.000 |
Why?
|
| Cholangiography | 1 | 1979 | 181 | 0.000 |
Why?
|
| Hyperinsulinism | 1 | 1982 | 400 | 0.000 |
Why?
|
| Animals | 4 | 1985 | 168467 | 0.000 |
Why?
|
| Video Recording | 1 | 1984 | 967 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1989 | 4001 | 0.000 |
Why?
|
| Prevalence | 1 | 1996 | 15732 | 0.000 |
Why?
|
| Dura Mater | 1 | 1980 | 290 | 0.000 |
Why?
|
| Hyperemia | 1 | 1979 | 221 | 0.000 |
Why?
|
| Coronary Circulation | 1 | 1983 | 1569 | 0.000 |
Why?
|
| Scalp | 1 | 1980 | 389 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1985 | 1182 | 0.000 |
Why?
|
| Venous Pressure | 1 | 1977 | 56 | 0.000 |
Why?
|
| Hindlimb | 1 | 1979 | 513 | 0.000 |
Why?
|
| Systole | 1 | 1979 | 936 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1979 | 1496 | 0.000 |
Why?
|
| Pelvis | 1 | 1980 | 733 | 0.000 |
Why?
|
| Fluoroscopy | 1 | 1979 | 947 | 0.000 |
Why?
|
| Hypoglycemia | 1 | 1982 | 883 | 0.000 |
Why?
|
| Cadaver | 1 | 1979 | 1358 | 0.000 |
Why?
|
| Celiac Artery | 1 | 1974 | 65 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1974 | 397 | 0.000 |
Why?
|
| Phlebography | 1 | 1975 | 326 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1990 | 9177 | 0.000 |
Why?
|
| Gastrointestinal Diseases | 1 | 1981 | 1200 | 0.000 |
Why?
|
| Biopsy, Needle | 1 | 1977 | 1626 | 0.000 |
Why?
|
| Massachusetts | 1 | 1984 | 8830 | 0.000 |
Why?
|
| Fatty Liver | 1 | 1977 | 790 | 0.000 |
Why?
|
| Blood Coagulation | 1 | 1977 | 1154 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1983 | 6377 | 0.000 |
Why?
|
| Child, Preschool | 2 | 1985 | 42230 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1986 | 9002 | 0.000 |
Why?
|
| Intestines | 1 | 1977 | 1909 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1977 | 9319 | 0.000 |
Why?
|